SEC Form SC 13G filed by MacroGenics Inc.

2/14/24 10:04:37 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MGNX alert in real time by email

SC 13G 1 mgnx13gdec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) MACROGENICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 556099109 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,963,905 6. Shared Voting Power* 0 7. Sole Dispositive Power* 5,639,994 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,639,994 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 9.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: MACROGENICS INC Item 1(b) Address of Issuer's Principal Executive Offices: 9704 MEDICAL CENTER DRIVE, Rockville, MARYLAND 20850 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 556099109 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: February 14, 2024 Signature: /s/ Armando Capasso Name & Title: Armando Capasso, Vice President 12/31/2023

Get the next $MGNX alert in real time by email

Recent Analyst Ratings for

$MGNX

Date	Price Target	Rating	Analyst
4/10/2026	$9.00	Neutral → Buy	B. Riley Securities
9/17/2025	$3.00	Overweight	Barclays
11/7/2024		Mkt Outperform → Mkt Perform	JMP Securities
8/1/2024		Buy → Neutral	BTIG Research
7/31/2024	$18.00 → $5.00	Buy → Neutral	B. Riley Securities
7/31/2024		Buy → Neutral	Guggenheim
5/10/2024	$24.00 → $8.00	Outperform → Market Perform	BMO Capital Markets
5/10/2024	$29.00 → $7.00	Buy → Hold	Stifel

More analyst ratings

SEC Form SC 13G filed by MacroGenics Inc.

2/14/24 10:04:37 AM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MGNX alert in real time by email

Recent Analyst Ratings for

$MGNX

Date	Price Target	Rating	Analyst
4/10/2026	$9.00	Neutral → Buy	B. Riley Securities
9/17/2025	$3.00	Overweight	Barclays
11/7/2024		Mkt Outperform → Mkt Perform	JMP Securities
8/1/2024		Buy → Neutral	BTIG Research
7/31/2024	$18.00 → $5.00	Buy → Neutral	B. Riley Securities
7/31/2024		Buy → Neutral	Guggenheim
5/10/2024	$24.00 → $8.00	Outperform → Market Perform	BMO Capital Markets
5/10/2024	$29.00 → $7.00	Buy → Hold	Stifel

More analyst ratings

SEC Form SC 13G filed by MacroGenics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MGNX

SEC Form SC 13G filed by MacroGenics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MGNX

$MGNX
FDA approvals

FDA Approval for MARGENZA issued to MACROGENICS INC

FDA Approval for MARGENZA

$MGNX
Insider Trading

Director O'Brien Federica F. converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)

Director Jackson Scott Thomas converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)

Director Heiden William K converted options into 3,750 shares, increasing direct ownership by 3% to 114,750 units (SEC Form 4)

$MGNX
Insider Purchases

Director Heiden William K bought $150,515 worth of shares (100,000 units at $1.51), increasing direct ownership by 909% to 111,000 units (SEC Form 4)

Biotech Target N V bought $669,585 worth of shares (150,000 units at $4.46), increasing direct ownership by 2% to 9,929,963 units (SEC Form 4)

$MGNX
SEC Filings

MacroGenics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form SCHEDULE 13G filed by MacroGenics Inc.

MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MGNX
Press Releases

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

$MGNX
Analyst Ratings

MacroGenics upgraded by B. Riley Securities with a new price target

Barclays resumed coverage on MacroGenics with a new price target

MacroGenics downgraded by JMP Securities

$MGNX
Leadership Updates

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

MacroGenics Announces Leadership Transition

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

$MGNX
Large Ownership Changes